CD19 and leukemia: Such patients should have CD19+ leukemia (applicable in B‐cell lineage), have controllable disease during product manufacturing, be able to tolerate severe toxicities (like cytokine release syndrome and neurotoxicity), and their care is mainly available at tertiary centers.